findmyKOL

Daniel Deangelo, MD

Enriched profile

Chief, Division of Leukemia; Professor of Medicine, Harvard Medical School; Institute Physician · Dana-Farber Cancer Institute

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyHematology / OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2025–2026

Daniel Deangelo is Chief, Division of Leukemia; Professor of Medicine, Harvard Medical School; Institute Physician at Dana-Farber Cancer Institute. OpenAlex indexes 933 publications with 38,550 citations (h-index 93); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 17 Aug 2026

Overview

Updated 14 Oct 2026

Daniel J. DeAngelo, MD,PHD, is Chief, Division of Leukemia at Dana-Farber Cancer Institute, Boston, MA. The public record shows 933 publications with 38,550 citations (h-index 93), centered on Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 25 companies, 2 NIH-funded awards (2025–2026).

  • Most recent indexed publication: 2026 · Cancer research communications
  • Top research focus: Acute Myeloid Leukemia Research
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 25 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)10 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma4 trialsLeukemia, Myeloid, Acute3 trialsLymphoma1 trialMDS / MPN1 trialPrimary Myelofibrosis1 trialMetaplasia1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchCAR-T cell therapy research

Drugs & molecules

across trials, industry payments and publications
Tecartusgeneric · Brexucabtagene autoleucelClinical trials—Industry payments12Publications1Besponsageneric · Inotuzumab ozogamicinClinical trials—Industry payments5Publications5Onureggeneric · AzacitidineClinical trials—Industry payments8Publications2Iclusiggeneric · PonatinibClinical trials—Industry payments5Publications4Rylazegeneric · AsparaginaseClinical trials—Industry payments7Publications1Scemblixgeneric · AsciminibClinical trials—Industry payments2Publications6Rydaptgeneric · MidostaurinClinical trials—Industry payments2Publications1Vanflytageneric · QuizartinibClinical trials—Industry payments6Publications—ImetelstatClinical trials—Industry payments5Publications—Blincytogeneric · BlinatumomabClinical trials—Industry payments3Publications—Asparlasgeneric · Calaspargase pegolClinical trials—Industry payments2Publications—Revuforjgeneric · RevumenibClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Novartis Pharmaceuticals CorporationClinical trials—Industry payments13Blueprint Medicines CorporationClinical trials—Industry payments12Kite Pharma, Inc.Clinical trials—Industry payments12Celgene CorporationClinical trials—Industry payments10Pfizer Inc.Clinical trials—Industry payments9Jazz Pharmaceuticals Inc.Clinical trials—Industry payments8Daiichi Sankyo Inc.Clinical trials—Industry payments6GlaxoSmithKline, LLC.Clinical trials—Industry payments6Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments6Adaptive Biotechnologies CorporationClinical trials—Industry payments5Dana-Farber Cancer InstituteClinical trials5Industry payments—Geron CorporationClinical trials—Industry payments5Amgen Inc.Clinical trials—Industry payments4AstraZeneca Pharmaceuticals LPClinical trials—Industry payments3Servier Pharmaceuticals LLCClinical trials—Industry payments3E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments2GlycoMimetics IncorporatedClinical trials2Industry payments—ImmunoGen, Inc.Clinical trials—Industry payments2Syndax Pharmaceuticals, Inc.Clinical trials—Industry payments2AbbVie Inc.Clinical trials—Industry payments1Alliance for Clinical Trials in OncologyClinical trials1Industry payments—Astellas Pharma US IncClinical trials—Industry payments1Autolus IncClinical trials—Industry payments1CTI BioPharma Corp.Clinical trials—Industry payments1Institut de Recherches Internationales ServierClinical trials1Industry payments—Merck Sharp & Dohme LLCClinical trials—Industry payments1National Cancer Institute (NCI)Clinical trials1Industry payments—Rigel Pharmaceuticals, Inc.Clinical trials—Industry payments1Sobi, IncClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
933publications

Distinct works indexed by OpenAlex, matched via ORCID; 56 in PubMed.

38,550citations

Total citations across indexed works.

93h-index

Hirsch index (OpenAlex). i10-index 362.

Clinical & industry

trials, payments and federal funding
10clinical trials

Investigator role on registered studies.

View trials ↓
25companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2025–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record
  • Co-chair emeritus

    National Cancer Institute (NCI) Leukemia Steering Committee

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
  • Member

    NCCN Guidelines Committees (CML and ALL)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
  • Member

    World CML Registry Steering Committee (Novartis)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:

All 10 trial records: search, sort and filter.Explore →

Industry payments

Updated 14 Oct 2026

25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 46 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    77.7%
    Kinase inhibitor49.2%
    Jakafi35%Imatinib Mesylate27%Ayvakit17%Sprycel14%Vonjo6%
    Part D<11 patients
    Antimetabolite18.3%
    Hydroxyurea100%
    Part D≥29 patients

    + 3 more classes in this area

  • Nervous system

    4.7%
    Benzodiazepine2.8%
    Lorazepam100%
    Part D<11 patients
    Opioid Agonist1.8%
    Oxycodone Hcl100%
    Part D<11 patients

  • Metabolism & gastrointestinal

    4.4%
    Corticosteroid4.4%
    Prednisone100%
    Part D<11 patients
All 7 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

2 NIH research awards on record, funded 2025–2026 per NIH RePORTER. The latest:

Congress activity

Updated 14 Oct 2026

229 congress contributions (2005–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:

All 229 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 56 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
    1,698 citations2003
    doi.org ↗
  2. 02
    Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    1,474 citations2017
    doi.org ↗
  3. 03
    MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
    1,416 citations2006
    doi.org ↗
  4. 04
    Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
    1,375 citations2016
    doi.org ↗
  5. 05
    A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
    1,127 citations2013
    doi.org ↗
All 933 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Richard M. Stone355Martha Wadleigh181Ilene Galinsky161Marlise R. Luskin154Donna Neuberg128Hagop M. Kantarjian127Jacqueline S. Garcia104Eric S. Winer97David P. Steensma91Anjali S. Advani90Jörge E. Cortes85Michael W. Deininger82Wendy Stock78Jason Gotlib71Evan C. Chen58Tracy I. George57Harry P. Erba56Maximilian Stahl55Shai Shimony55Moshe Talpaz53Elias Jabbour53Erik Vandendries51Amir T. Fathi51Delphine Réa51Deepti Radia49Andreas Hochhaus49Lewis B. Silverman49Robert J. Soiffer49R. Coleman Lindsley49Gregory A. Abel49Jeremy Ryan48Anthony Letai47Stephen E. Sallan43Rebecca Leonard42Timothy P. Hughes42Guido Marcucci41Ryan D. Cassaday41Philip C. Amrein40Eunice S. Wang40Matthias Stelljes39

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/daniel-deangelo-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    physicianresources.dana-farber.org/videos/daniel-deangelo-md-phd-on-a-novel-systemic-mastocytosis-sm-drug

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗
  • X / Twitter

    x.com/DanaFarber/status/1865941582647799921

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • X / Twitter

    x.com/OncLive/status/1853965525547917584

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • LinkedIn

    LinkedIn profile (Dana-Farber Cancer Institute)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • Doximity

    Doximity profile (Oncology, Boston, MA)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Hematology

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Board Certified

    Medical Oncology

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • MD

    Albert Einstein College of Medicine

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
  • BS

    Chemistry, University of California, Berkeley

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
  • PhD

    Molecular Genetics, Albert Einstein College of Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
  • Internal Medicine Residency

    Massachusetts General Hospital

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Clinical Fellowship

    Hematology & Oncology, Brigham and Women's Hospital / Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Board Certified

    Internal Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗

Editorial & leadership roles

journal and society appointments
  • Clinical Director

    Adult Leukemia Program, Dana-Farber Cancer Institute

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Attending Physician

    Brigham and Women's Hospital

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
  • Member

    Developmental Therapeutics and Leukemia Programs, Dana-Farber/Harvard Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.